The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry - Based approaches: Current strategies for candidate verification

Clinical Chemistry

Volumn 56, Issue 2, 2010, Pages 212-222

  Makawita, Shalini ^a   Diamandis, Eleftherios P ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; C REACTIVE PROTEIN; HUMAN GROWTH HORMONE; LEPTIN; MYELIN BASIC PROTEIN; MYOGLOBIN; PROSTATE SPECIFIC ANTIGEN; RETINOL BINDING PROTEIN; SERUM AMYLOID P; TUMOR MARKER;

CANCER DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN TARGETING; PROTEOMICS; REVIEW;

HUMANS; LIMIT OF DETECTION; MASS SPECTROMETRY; NEOPLASM PROTEINS; NEOPLASMS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 75749095246     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.127019     Document Type: Review

References (65)

1. Boyle P, Levin B. World cancer report 2008. International Agency for Research on Cancer. http://www.iarc.fr/en/publications/pdfs-online/wcr/ (Accessed July 2009).
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Korner M, Miller LJ. Alternative splicing of pre-mRNA in cancer focus on G protein-coupled peptide hormone receptors. Am J Pathol 2009;175:461-72.
4. Zhu J, Yao X. Use of DNA methylation for cancer detection: promises and challenges. Int J Biochem Cell Biol 2009;41:147-54.
5. Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 2008;23:81-94.
6. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009;55:623-31.
7. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83.
8. Kulasingam V, Diamandis EP. Tissue culture-based breast cancer biomarker discovery platform. Int J Cancer 2008;123:2007-12.
9. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008;5:588-99.
10. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008;452:571-9.
11. Wang P, Whiteaker JR, Paulovich AG. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol Ther 2009;8:1083-94.
12. Gramolini AO, Peterman SM, Kislinger T. Mass spectrometry-based proteomics: a useful tool for biomarker discovery? Clin Pharmacol Ther 2008;83:758-60.
13. Ludwig JA, Weinstein JN. biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
14. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79.
15. Zhao Y, Lee WN, Xiao GG. Quantitative proteomics and biomarker discovery in human cancer. Expert Rev Proteomics 2009;6:115-8.
16. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008;2:1386-402.
17. Carr SA, Anderson L. Protein quantitation through mass spectrometry: the way out of biomarker purgatory [Editorial]? Clin Chem 2008;54:1749-52.
18. Campbell AM. Production and purification of antibodies. In: Diamandis EP, Christopoulos TK, eds. Immunoassays. San Diego: Academic Press; 1996. p 96-115.
19. Sardana G, Jung K, Stephan C, Diamandis EP. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008;7:3329-38.
20. Brunner E, Ahrens CH, Mohanty S, Baetschmann H, Loevenich S, Potthast F, et al. A high-quality catalog of the Drosophila melanogaster proteome. Nat Biotechnol 2007;25:576-83.
21. Faca VM, Ventura AP, Fitzgibbon MP, Pereira-Faca SR, Pitteri SJ, Green AE, et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 2008;3:e2425.
22. Bousette N, Kislinger T, Fong V, Isserlin R, Hewel JA, Emil A, et al. Large-scale characterization and analysis of the murine cardiac proteome. J Proteome Res 2009;8:1887-901 .
23. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods 2009;6:359-62.
24. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:1229-39.
25. Yocum AK, Chinnaiyan AM. Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. Brief Funct Genomic Proteomic 2009;8:145-57.
26. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008;4:222.
27. Han B, Higgs RE. Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers. Brief Funct Genomic Proteomic 2008;7:340-54.
28. Lin S, Shaler TA, Becker CH. Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in single-quandrupole ion trap. Anal Chem 2006;78:5762-7.
29. Fusaro VA, Mani DR, Mesirov JP, Carr SA. Prediction of high-responding peptides for targeted protein assays by mass spectrometry. Nat Biotechnol 2009;27:190-8.
30. Baty JD, Robinson PR. Single and multiple ion recording techniques for the analysis of diphenylhydantoin and its major metabolite in plasma. Biomed Mass Spectrom 1977;4:36-41.
31. Zakett D, Flynn RGA, Cooks RG. Chlorine isotope effects in mass spectrometry by multiple reaction monitoring. J Phys Chem 1978;82:2359.
32. Barr JR, Maggio VL, Patterson DG Jr, Cooper GR, Henderson LO, Turner WE, et al. Isotope dilution mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin Chem 1996;42:1676-82.
33. Barnidge DR, Goodmanson MK, Klee GG, Muddiman DC. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res 2004;3:644-52.
34. 13C-labeled peptide standards. Proteomics 2004;4:1175- 86.
35. Wu SL, Amato H, Biringer R, Choudhary G, Shieh P, Hancock WS. Targeted proteomics of low-level proteins in human plasma by LC/MSn: using human growth hormone as a model system. J Proteome Res 2002;1:459-65.
36. Kiernan UA, Addobbati R, Nedelkov D, Nelson RW. Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. J Proteome Res 2006;5:1682-7.
37. Janecki DJ, Bemis KG, Tegeler TJ, Sanghani PC, Zhai L, Hurley TD, et al. A multiple reaction monitoring method for absolute quantification of the human liver alcohol dehydrogenase ADH1C1 isoenzyme. Anal Biochem 2007;369:18-26.
38. Yang Z, Hayes M, Fang X, Daley MP, Ettenberg S, Tse FLS. LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2S-solid-phase extraction cleanup. Anal Chem 2007;79:9294-301.
39. Fortin T, Salvador A, Charrier JP, Zenz C, Lacoux X, Morla A, et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteomics 2009;8:1006-15.
40. Williams DK, Muddiman DC. Absolute quantification of C-reactive protein in human plasma derived from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution mass spectrometry. J Proteome Res 2009;8:1085-90.
41. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007;6:2212-29.
42. Keshishian H, Addona T, Burgess M, Mani Dr, ShiX, Kuhn E, et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2009;8:2339-49.
43. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88.
44. Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, Hardie DB, et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009;8:1860-77.
45. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27:633-41.
46. Kulasingam V, Smith CR, Batruch I, Buckler A, Jeffery DA, Diamandis EP. "Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap. J Proteome Res 2008;7:640-7.
47. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
48. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 2009;3:33-44.
49. Nicol GR, Han M, Kim J, Birse CE, Brand E, Nguyen A, et al. Use of immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. Mol Cell Proteomics 2008;7:1974-82.
50. Berna M, Ackermann B. Increased throughput for low-abundance protein biomarker verification by liquid chromatography/tandem mass spectrometry. Anal Chem 2009;81:3950-6.
51. Zhang H, Li X, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660-6.
52. Stahl-Zeng J, Lange V, Ossola R, Eckhardt K, Krek W, Aebersold R, et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteomics 2007;6:1809-17.
53. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 2004;3:235-44.
54. Anderson NL, Jackson A, Smith D, Hardie D, Borchers C, Pearson TW. SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics 2009;8:995-1005.
55. Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, et al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 2009;55:1108-17.
56. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of throglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008;54:1796-804.
57. Wunderlich G, Zophel K, Crook L, Smith S, Smith BR, Franke WG. A high-sensitivity enzyme linked immunosorbent assay for serum thyroglobulin. Thyroid 2001;11:819-24.
58. Anderson NL, Anderson NG, Pearson TW. Borchers CH, Paulovich AG, Patterson SD, et al. A human proteome detection and quantitation project. Mol Cell Proteomics 2009;8:883-6.
59. Craig R, Cortens JP, Beavis RC. Open source system for analyzing, validating, and storing protein identification data. J Proteome Res 2004;3:1234-42.
60. Lazar IM, Yang X. MRM screening/biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides. BMC Cancer 2009;9:96.
61. Mallick P, Schirle M, Chen SS, Flory MR, Lee H, Martin D, et al. Computational prediction of proteotypic peptides for quantitative proteomics. Nat Biotechnol 2007;25:125-31.
62. Sherwood C, Eastham A, Peterson A, Eng JK, Shteynberg D, Mendoza L, et al. MaRiMba: a software application for spectral library-based MRM transition list assembly. J Proteome Res 2009;8:4396-405.
63. Mead JA, Bianco L, Ottone V, Barton C, Kay RG, Lilley KS, et al. MRMaid, the web-based tool for designing multiple reaction monitoring (MRM) transitions. Mol Cell Proteomics 2009;8:696-705.
64. Sherman J, McKay MJ, Ashman K, Molloy MP. How specific is my SRM?: The issue of precursor and product ion redundancy. Proteomics 2009;9:1120-3.
65. Diamandis EP, Hanash S, Lopez M, Carr S, Petricoin EF 3rd. Protein quantification by mass spectrometry: is it ready for prime time? Clin Chem 2009;55:1427-30.